Top Globe News – Lifestyle
Author:
Rezolute, Inc.
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
May 1, 2026
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
April 28, 2026
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
March 24, 2026